touchFEATURE The role of RNA-based next-generation sequencing in identifying pathogenic gene fusions
A review of next-generation sequencing methods for identifying actionable gene fusions and improving outcomes in cancer patients.
The promise of precision oncology
Dr Benjamin Weinberg discusses the benefits of precision oncology for identifying and exploiting actionable targets.
view bio and disclosures 1/4 Next ChapterThe problem of pathogenic gene fusions
Dr Benjamin Weinberg discusses the outcomes associated with pathogenic gene fusions, with a focus on NRG1.
view bio and disclosures 2/4 Next ChapterOncologist perspective - The potential of RNA-based NGS
Dr Benjamin Weinberg discusses the role of RNA-based NGS for identifying actionable gene fusions in the clinic.
view bio and disclosures 3/4 Next ChapterPathologist perspective - The potential of RNA-based NGS
A perspective from pathologist Dr Joeffrey Chahine, PhD who discusses the role of RNA-based NGS.
view bio and disclosures 4/4 Leave FeedbackOverview & Learning Objectives
Overview
Pathogenic gene fusions are associated with poor survival in patients with some fusion-driven cancers.1,2 In this activity, a leading expert outlines the clinical impact of gene fusions and reviews the next-generation sequencing (NGS) methods that clinicians can use to help identify actionable gene fusions that may be targeted with appropriate therapy.
Learning Objectives
After watching this activity, participants should be better able to:
- Discuss the importance of identifying actionable targets in patients with cancer
- Describe the impact of pathogenic gene fusions on clinical outcomes
- Describe key differences between RNA-based and DNA-based NGS
Faculty & Disclosures
Dr Benjamin Weinberg, MD
Associate Professor of Medicine and attending physician
Dr Benjamin Weinberg, MD is an Associate Professor of Medicine and attending physician. He specializes in gastrointestinal oncology and sarcoma. His research includes the development of new therapies for colorectal and pancreatic cancers, which includes the molecular characterization of mutations and actionable targets.
Disclosures: speaker’s fees from Merus
Dr Joeffrey Chahine, PhD
Technical Director Molecular Diagnostics Laboratory
Disclosures: speaker’s fees from Merus
References
- Dhanasekaran SM, et al. Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes. Nat Commun. 2014;5:5893.
- Nikanjam M, et al. Targeting fusions for improved outcomes in oncology treatment. Cancer. 2020;126:1315–21.
